{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:05:45Z","timestamp":1767773145241,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-\u03b1) antibodies.<\/jats:p>","DOI":"10.3390\/pathogens10050535","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:30:41Z","timestamp":1619692241000},"page":"535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test"],"prefix":"10.3390","volume":"10","author":[{"given":"Anna","family":"Colombo","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9910-3514","authenticated-orcid":false,"given":"Mauro","family":"Giuffr\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-7011","authenticated-orcid":false,"given":"Lory Saveria","family":"Croc\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-0826","authenticated-orcid":false,"given":"Sergio","family":"Venturini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Azienda Sanitaria Friuli Occidentale, Pordenone Hospital, 33170 Pordenone, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Sablich","sequence":"additional","affiliation":[{"name":"IBD Unit, Department of Gastroenterology, Azienda Sanitaria Friuli Occidentale, Pordenone Hospital, 33170 Pordenone, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0149-2918(99)80015-0","article-title":"Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn\u2019s disease","volume":"21","author":"Mouser","year":"1999","journal-title":"Clin. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/138945010790309902","article-title":"Mucosal Healing and anti TNFs in IBD","volume":"11","author":"Assche","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor \u03b1\u2013Neutralizing Agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1086\/429994","article-title":"Tumor Necrosis Factor and Chemokine Interactions in the Formation and Maintenance of Granulomas in Tuberculosis","volume":"41","author":"Lin","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_6","unstructured":"(2021, February 09). QuantiFERON\u00ae-TB Gold Plus (QFT\u00ae-Plus) ELISA Package Insert. Available online: https:\/\/www.qiagen.com\/us\/products\/diagnostics-and-clinical-research\/tb-management\/quantiferon-tb-gold-plus-us\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1007025717379","article-title":"PR Murray, EJ Baron, MA Pfaller, FC Tenover and RH Yolken, eds. Manual of Clinical Microbiology","volume":"146","author":"Lehmann","year":"1999","journal-title":"Mycopathologia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12026-011-8229-7","article-title":"Latent tuberculosis: What the host \u201csees\u201d?","volume":"50","author":"Gideon","year":"2011","journal-title":"Immunol. Res."},{"key":"ref_10","unstructured":"(2021, February 09). ANNEX 4 TB Burden Estimates, Notifications and Treatment Outcomes for Individual Countries and Territories, Who Regions and the World. Available online: https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2018_annex4.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/MMBR.00010-14","article-title":"Latent Tuberculosis Infection: Myths, Models, and Molecular Mechanisms","volume":"78","author":"Dutta","year":"2014","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2019.00008","article-title":"Diagnostic and Therapeutic Strategies for Peritoneal Tuberculosis: A Review","volume":"7","author":"Wu","year":"2019","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_13","first-page":"131","article-title":"Intestinal and peritoneal tuberculosis: Changing trends over 10 years and a review of 80 patients","volume":"48","author":"Akgun","year":"2005","journal-title":"Can. J. Surg."},{"key":"ref_14","unstructured":"Frieden, T.R., Jaffe, M.W.H., Stephens, J.W., Thacker, S.B., Shaw, F.E., Starr, S.R.S.T.M., Doan, Q.M., Phyllis King, M.H., Holtzman, D., and John Iglehart, G.K. (2021, February 09). Department of Health and Human Services Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection-United States, 2010 Editorial and Production Staff, Available online: www.cdc.gov\/mmwr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Turon","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jinf.2008.02.011","article-title":"Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection","volume":"56","author":"Harada","year":"2008","journal-title":"J. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JCM.00438-18","article-title":"Comparative evaluation of quantiFERON-TB gold in-tube and quantiFERON-TB gold plus in diagnosis of latent tuberculosis infection in immunocompromised patients","volume":"56","author":"Ryu","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: A systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-008-0519-1","article-title":"Performance of two commercial blood IFN-\u03b3 release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-\u03b1 treatment","volume":"27","author":"Bocchino","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10067-016-3462-z","article-title":"The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis","volume":"36","author":"Cuomo","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","article-title":"Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases","volume":"74","author":"Hatzara","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","article-title":"Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: A descriptive study on the GETAID cohort","volume":"10","author":"Abitbol","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.crohns.2012.02.003","article-title":"Primary tuberculous peritonitis during infliximab therapy for Crohn\u2019s disease","volume":"6","author":"Kraus","year":"2012","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4166\/kjg.2019.74.3.168","article-title":"Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis","volume":"74","author":"Jun","year":"2019","journal-title":"Korean J. Gastroenterol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/5\/535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:55:15Z","timestamp":1760162115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/5\/535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["pathogens10050535"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10050535","relation":{},"ISSN":["2076-0817"],"issn-type":[{"type":"electronic","value":"2076-0817"}],"subject":[],"published":{"date-parts":[[2021,4,29]]}}}